The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...
In an interview with BioPharma Dive, the veteran biotech CEO said there remains a “significant opportunity” for young ...
The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback